Premium
Front Cover: Structure‐Guided Design of a Group B Streptococcus Type III Synthetic Glycan–Conjugate Vaccine (Chem. Eur. J. 31/2020)
Author(s) -
Oldrini Davide,
Bino Linda,
Arda Ana,
Carboni Filippo,
Henriques Pedro,
Angiolini Francesca,
Quintana Jon I.,
Calloni Ilaria,
Romano Maria R.,
Berti Francesco,
JimenezBarbero Jesus,
Margarit Immaculada,
Adamo Roberto
Publication year - 2020
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.202002015
Subject(s) - glycan , epitope , conjugate , glycobiology , conjugate vaccine , chemistry , oligosaccharide , streptococcus , computational biology , stereochemistry , antibody , biochemistry , biology , immunology , bacteria , glycoprotein , streptococcus pneumoniae , mathematics , genetics , mathematical analysis , antibiotics
Group B Streptococcus III has been considered a model of highly complex glycan epitope. Based on the X‐ray crystallographic structure of a polysaccharide fragment‐mAb complex, a hexasaccharide was synthesized comprising the positions involved in binding. After conjugation to a carrier protein and in vivo testing, the oligosaccharide was as efficacious as the natural polysaccharide in inducing protective antibodies. This study underlines the role of structural glycobiology in simplifying the design of vaccines based on complex bacterial polysaccharides. More information can be found in the Full Paper by R. Adamo et al. on page 7018.